Detalhe da pesquisa
1.
An international simulated-use study to assess nurses' preferences between two lanreotide syringes for patients with neuroendocrine tumours or acromegaly (PRESTO 3).
J Endocrinol Invest;
47(2): 421-432, 2024 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37550552
2.
Pasireotide effects on biochemical control and glycometabolic profile in acromegaly patients switched from combination therapies or unconventional dosages of somatostatin analogs.
J Endocrinol Invest;
47(3): 683-697, 2024 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37695461
3.
Improved overall survival in patients developing endocrine toxicity during treatment with nivolumab for advanced non-small cell lung cancer in a prospective study.
J Endocrinol Invest;
2024 Apr 29.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38683497
4.
Disease control of acromegaly does not prevent excess mortality in the long term: results of a nationwide survey in Italy.
J Endocrinol Invest;
2024 Jan 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38214852
5.
Impact of microscopic extrathyroidal extension on differentiated thyroid cancer post-surgical risk of recurrence: a retrospective analysis.
J Endocrinol Invest;
46(10): 2157-2164, 2023 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36976482
6.
The effect of sodium restriction on iodine prophylaxis: a review.
J Endocrinol Invest;
45(6): 1121-1138, 2022 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35079975
7.
Clinical and radiological presentation of parasellar ectopic pituitary adenomas: case series and systematic review of the literature.
J Endocrinol Invest;
45(8): 1465-1481, 2022 Aug.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35147925
8.
PRRT: identikit of the perfect patient.
Rev Endocr Metab Disord;
22(3): 563-579, 2021 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32978685
9.
Safety and effectiveness of Omnitrope® in patients with growth hormone deficiency: snapshot analysis of PATRO Adults study in the Italian population.
J Endocrinol Invest;
44(2): 327-337, 2021 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32507990
10.
Impact of the SARS-CoV2 pandemic dissemination on the management of neuroendocrine neoplasia in Italy: a report from the Italian Association for Neuroendocrine Tumors (Itanet).
J Endocrinol Invest;
44(5): 989-994, 2021 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32803662
11.
Somatostatin receptor expression and patients' response to targeted medical treatment in pituitary tumors: evidences and controversies.
J Endocrinol Invest;
43(11): 1543-1553, 2020 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32557353
12.
Arthropathy in acromegaly: a questionnaire-based estimation of motor disability and its relation with quality of life and work productivity.
Pituitary;
22(5): 552-560, 2019 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31032537
13.
Appropriate management of growth hormone deficiency during the age of transition: an Italian Delphi consensus statement.
J Endocrinol Invest;
46(1): 189-200, 2023 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35960476
14.
PD-L1 expression, BRAF and TERT mutation in a cohort of aggressive thyroid cancers: case series from a single-centre experience.
J Endocrinol Invest;
46(10): 2185-2188, 2023 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36933169
15.
Analysis of characteristics and outcomes by growth hormone treatment duration in adult patients in the Italian cohort of the Hypopituitary Control and Complications Study (HypoCCS).
J Endocrinol Invest;
41(11): 1259-1266, 2018 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29536433
16.
Anti-tumoral effects of somatostatin analogs: a lesson from the CLARINET study.
J Endocrinol Invest;
40(11): 1265-1269, 2017 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28550464
17.
Long-term safety and efficacy of Omnitrope® in adults with growth hormone deficiency: Italian interim analysis of the PATRO Adults study.
J Endocrinol Invest;
40(6): 669-678, 2017 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28161880
18.
Rare diseases in clinical endocrinology: a taxonomic classification system.
J Endocrinol Invest;
38(2): 193-259, 2015 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25376364
19.
Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs.
J Endocrinol Invest;
36(1): 38-43, 2013 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22472799
20.
Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study.
J Cell Mol Med;
16(7): 1563-72, 2012 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21883896